Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Lead Halide Perovskite Quantum Dots to Enhance the Power Conversion Efficiency of Organic Solar Cells.

Guijarro N, Yao L, Le Formal F, Wells RA, Liu Y, Darwich BP, Navratilova L, Cho HH, Yum JH, Sivula K.

Angew Chem Int Ed Engl. 2019 Jul 22. doi: 10.1002/anie.201906803. [Epub ahead of print] Review.

PMID:
31328858
2.

The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.

Vijenthira A, Premkumar D, Callum J, Lin Y, Wells RA, Chodirker L, Lenis M, Mamedov A, Buckstein R.

Leuk Res. 2019 Jan;76:76-81. doi: 10.1016/j.leukres.2018.12.002. Epub 2018 Dec 11.

PMID:
30580105
3.

The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo.

Ichim CV, Dervovic DD, Chan LSA, Robertson CJ, Chesney A, Reis MD, Wells RA.

Biomark Res. 2018 Dec 7;6:36. doi: 10.1186/s40364-018-0149-4. eCollection 2018.

4.

Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.

Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Shamy A, Elemary M, Wells RA.

Leuk Res. 2018 Nov;74:21-41. doi: 10.1016/j.leukres.2018.09.005. Epub 2018 Sep 19. Review.

PMID:
30286330
5.

How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry.

Patriquin CJ, Kiss T, Caplan S, Chin-Yee I, Grewal K, Grossman J, Larratt L, Marceau D, Nevill T, Sutherland DR, Wells RA, Leber B.

Eur J Haematol. 2019 Jan;102(1):36-52. doi: 10.1111/ejh.13176. Epub 2018 Oct 25. Review.

PMID:
30242915
6.

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.

Röth A, Rottinghaus ST, Hill A, Bachman ES, Kim JS, Schrezenmeier H, Terriou L, Urbano-Ispizua Á, Wells RA, Jang JH, Kulasekararaj AG, Szer J, Aguzzi R, Damokosh AI, Shafner L, Lee JW.

Blood Adv. 2018 Sep 11;2(17):2176-2185. doi: 10.1182/bloodadvances.2018020644.

7.

Spinel Structural Disorder Influences Solar-Water-Splitting Performance of ZnFe2 O4 Nanorod Photoanodes.

Zhu X, Guijarro N, Liu Y, Schouwink P, Wells RA, Le Formal F, Sun S, Gao C, Sivula K.

Adv Mater. 2018 Jul 5:e1801612. doi: 10.1002/adma.201801612. [Epub ahead of print]

PMID:
29975805
8.

Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.

Cull AH, Mahendru D, Snetsinger B, Good D, Tyryshkin K, Chesney A, Ghorab Z, Reis M, Buckstein R, Wells RA, Rauh MJ.

Leuk Res. 2018 Feb;65:5-13. doi: 10.1016/j.leukres.2017.12.003. Epub 2017 Dec 6.

PMID:
29227812
9.

An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis.

Abegunde SO, Buckstein R, Wells RA, Rauh MJ.

Exp Hematol. 2018 Mar;59:60-65. doi: 10.1016/j.exphem.2017.11.002. Epub 2017 Nov 28.

PMID:
29195897
10.

A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.

Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R.

Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3.

PMID:
28975386
11.

Tet2 restrains inflammatory gene expression in macrophages.

Cull AH, Snetsinger B, Buckstein R, Wells RA, Rauh MJ.

Exp Hematol. 2017 Nov;55:56-70.e13. doi: 10.1016/j.exphem.2017.08.001. Epub 2017 Aug 18.

12.

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.

Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R.

Br J Haematol. 2017 Oct;179(1):83-97. doi: 10.1111/bjh.14825. Epub 2017 Jul 5.

PMID:
28677895
13.

Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.

Cox AR, Lam CJ, Rankin MM, Rios JS, Chavez J, Bonnyman CW, King KB, Wells RA, Anthony D, Tu JX, Kim JJ, Li C, Kushner JA.

Endocrinology. 2017 Jun 1;158(6):1701-1714. doi: 10.1210/en.2017-00027.

14.

Control of Surface and Edge Oxidation on Phosphorene.

Kuntz KL, Wells RA, Hu J, Yang T, Dong B, Guo H, Woomer AH, Druffel DL, Alabanza A, Tománek D, Warren SC.

ACS Appl Mater Interfaces. 2017 Mar 15;9(10):9126-9135. doi: 10.1021/acsami.6b16111. Epub 2017 Mar 1.

PMID:
28218508
15.

Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes.

Lin Y, Saskin A, Wells RA, Lenis M, Mamedov A, Callum J, Buckstein R.

Vox Sang. 2017 Jan;112(1):79-86. doi: 10.1111/vox.12455. Epub 2016 Oct 19.

PMID:
28097704
16.

Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.

Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM.

Br J Haematol. 2016 Jul;174(1):88-101. doi: 10.1111/bjh.14033. Epub 2016 Mar 15.

PMID:
26991631
17.

Myelodysplastic syndrome.

Wells RA, Buckstein R, Rezmovitz J.

CMAJ. 2016 Jul 12;188(10):751. doi: 10.1503/cmaj.151077. Epub 2016 Jan 4. No abstract available.

18.

Phosphorene: Synthesis, Scale-Up, and Quantitative Optical Spectroscopy.

Woomer AH, Farnsworth TW, Hu J, Wells RA, Donley CL, Warren SC.

ACS Nano. 2015 Sep 22;9(9):8869-84. doi: 10.1021/acsnano.5b02599. Epub 2015 Aug 21.

PMID:
26256770
19.

Monthly blood transfusions decrease after four months of azacitidine.

Tseng E, Prica A, Zhang L, Mittmann N, Seung SJ, Callum J, Kim T, Wells RA, Buckstein R.

Vox Sang. 2015 Aug;109(2):163-7. doi: 10.1111/vox.12266. Epub 2015 Apr 20.

PMID:
25899763
20.

Landscape of π-π and sugar-π contacts in DNA-protein interactions.

Wilson KA, Wells RA, Abendong MN, Anderson CB, Kung RW, Wetmore SD.

J Biomol Struct Dyn. 2016;34(1):184-200. doi: 10.1080/07391102.2015.1013157. Epub 2015 Feb 27.

PMID:
25723403
21.

Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromes.

Guirguis HR, Charbonneau LF, Tyono I, Wells RA, Cheung MC, Buckstein R.

Leuk Lymphoma. 2015 Feb;56(2):542-4. doi: 10.3109/10428194.2014.927457. Epub 2014 Jul 17. No abstract available.

PMID:
24882261
22.

Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.

Buckstein R, Kerbel R, Cheung M, Shaked Y, Chodirker L, Lee CR, Lenis M, Davidson C, Cussen MA, Reis M, Chesney A, Zhang L, Mamedov A, Wells RA.

Leuk Res. 2014 Jul;38(7):756-63. doi: 10.1016/j.leukres.2014.03.022. Epub 2014 Apr 5.

23.

Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.

Yee KW, Storring JM, Buckstein R, Wells RA, Xenocostas A, Kovacs MJ, Howson-Jan K, Wang ES, Battista K, Wang L, Oza AM, Ivy SP, Schuh AC.

Leuk Lymphoma. 2014 Nov;55(11):2669-71. doi: 10.3109/10428194.2014.900763. Epub 2014 Apr 22. No abstract available.

PMID:
24611649
24.

Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence.

Wells RA, Leber B, Zhu NY, Storring JM.

Curr Oncol. 2014 Feb;21(1):44-50. doi: 10.3747/co.21.1871.

25.

Initial transfusion intensity predicts survival in myelodysplastic syndrome.

Chan LS, Shapiro R, Buckstein R, Lin Y, Callum J, Chodirker L, Lee CD, Prica A, Lam A, Mamedov A, Wells RA.

Leuk Lymphoma. 2014 Oct;55(10):2296-300. doi: 10.3109/10428194.2013.878934. Epub 2014 Feb 24.

PMID:
24397595
26.

The aryl hydrocarbon receptor nuclear translocator (ARNT) modulates the antioxidant response in AML cells.

Gu C, Gonzalez J, Zhang T, Kamel-Reid S, Wells RA.

Leuk Res. 2013 Dec;37(12):1750-6. doi: 10.1016/j.leukres.2013.10.010. Epub 2013 Oct 22.

PMID:
24220583
27.

The orphan nuclear receptor Ear-2 (Nr2f6) is a novel negative regulator of T cell development.

Ichim CV, Dervović DD, Zúñiga-Pflücker JC, Wells RA.

Exp Hematol. 2014 Jan;42(1):46-58. doi: 10.1016/j.exphem.2013.09.010. Epub 2013 Oct 2.

PMID:
24096122
28.

Income and outcome in myelodysplastic syndrome: the prognostic impact of SES in a single-payer system.

England JT, Zhang L, Buckstein R, Lenis M, Li C, Earle C, Wells RA.

Leuk Res. 2013 Nov;37(11):1495-501. doi: 10.1016/j.leukres.2013.08.021. Epub 2013 Sep 8.

PMID:
24095584
29.

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.

Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16127-32. doi: 10.1073/pnas.1311055110. Epub 2013 Sep 16.

30.

Significant strength of charged DNA-protein π-π interactions: a preliminary study of cytosine.

Wells RA, Kellie JL, Wetmore SD.

J Phys Chem B. 2013 Sep 12;117(36):10462-74. doi: 10.1021/jp406829d. Epub 2013 Aug 30.

PMID:
23991905
31.

Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation.

Ichim CV, Wells RA.

J Transl Med. 2011 Aug 17;9:137. doi: 10.1186/1479-5876-9-137.

32.

Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.

Rauw J, Wells RA, Chesney A, Reis M, Zhang L, Buckstein R.

Leuk Res. 2011 Oct;35(10):1335-8. doi: 10.1016/j.leukres.2011.05.001. Epub 2011 Jun 24.

PMID:
21704372
33.

Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy.

Ichim CV, Atkins HL, Iscove NN, Wells RA.

Leukemia. 2011 Nov;25(11):1687-96. doi: 10.1038/leu.2011.137. Epub 2011 Jun 3.

34.

Correlation among nuclear localization of NuMA-RARα, deregulation of gene expression and leukemic phenotype of hCG-NuMA-RARα transgenic mice.

Sukhai MA, Thomas M, Hamadanizadeh SA, Xuan Y, Wells RA, Kamel-Reid S.

Leuk Res. 2011 May;35(5):670-6. doi: 10.1016/j.leukres.2010.12.009. Epub 2011 Jan 21.

PMID:
21255834
35.

5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

Buckstein R, Yee K, Wells RA; Canadian Consortium on Evidence-based Care in MDS.

Cancer Treat Rev. 2011 Apr;37(2):160-7. doi: 10.1016/j.ctrv.2010.05.006. Epub 2010 Jun 29. Review.

PMID:
20591575
36.

Cross-Talk between PPARs and the Partners of RXR: A Molecular Perspective.

Chan LS, Wells RA.

PPAR Res. 2009;2009:925309. doi: 10.1155/2009/925309. Epub 2009 Dec 20.

37.

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A.

Nat Med. 2010 Jan;16(1):49-58. doi: 10.1038/nm.2054. Epub 2009 Nov 8.

PMID:
19898489
38.

Iron overload in myelodysplastic syndromes.

Chodirker L, Wells RA.

Expert Rev Hematol. 2009 Jun;2(3):215-8. doi: 10.1586/ehm.09.23. No abstract available.

PMID:
21082962
39.

Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows.

Buckstein R, Jang K, Friedlich J, Zhang L, Reis M, Chesney A, Wells RA.

Leuk Res. 2009 Oct;33(10):1313-8. doi: 10.1016/j.leukres.2009.02.010. Epub 2009 Mar 17.

PMID:
19282029
40.

Evidence of functional interaction between NuMA-RARalpha and RXRalpha in an in vivo model of acute promyelocytic leukemia.

Sukhai MA, Thomas M, Xuan Y, Chan LS, Hamadanizadeh SA, Zhang T, Bharadwaj RR, Schuh AC, Wells RA, Kamel-Reid S.

Oncogene. 2008 Aug 7;27(34):4666-77. doi: 10.1038/onc.2008.106. Epub 2008 Apr 14.

PMID:
18408763
41.

Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.

Wells RA, Leber B, Buckstein R, Lipton JH, Hasegawa W, Grewal K, Yee K, Olney HJ, Larratt L, Vickars L, Tinmouth A.

Leuk Res. 2008 Sep;32(9):1338-53. doi: 10.1016/j.leukres.2008.02.021. Epub 2008 Apr 11.

PMID:
18405971
42.

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.

Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L, Von Lilienfeld-Toal M, Wells RA.

Ann Hematol. 2008 May;87(5):345-52. doi: 10.1007/s00277-008-0449-0. Epub 2008 Feb 12. Review.

43.

West Nile virus surveillance in East Baton Rouge Parish, Louisiana.

Gleiser RM, Mackay AJ, Roy A, Yates MM, Vaeth RH, Faget GM, Folsom AE, Augustine WF Jr, Wells RA, Perich MJ.

J Am Mosq Control Assoc. 2007 Mar;23(1):29-36.

PMID:
17536365
44.
45.

A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response.

Brandwein JM, Yang L, Schimmer AD, Schuh AC, Gupta V, Wells RA, Alibhai SM, Xu W, Minden MD.

Leukemia. 2007 Apr;21(4):821-4. Epub 2007 Jan 25. No abstract available.

PMID:
17252015
46.

Pathological splenic rupture: a rare complication of chronic myelomonocytic leukemia.

Goddard SL, Chesney AE, Reis MD, Ghorab Z, Brzozowski M, Wright FC, Wells RA.

Am J Hematol. 2007 May;82(5):405-8.

47.

First among equals: the cancer cell hierarchy.

Ichim CV, Wells RA.

Leuk Lymphoma. 2006 Oct;47(10):2017-27. Review.

PMID:
17071472
48.

Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.

Gu C, Ye T, Wells RA.

Leuk Res. 2006 Nov;30(11):1447-51. Epub 2006 May 15.

PMID:
16704876
49.

Differential lineage-specific regulation of murine CD45 transcription by Oct-1 and PU.1.

Kwon UK, Yen PH, Collins T, Wells RA.

Biochem Biophys Res Commun. 2006 May 26;344(1):146-54. Epub 2006 Mar 29.

PMID:
16616894
50.

Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia.

Gronda M, Brandwein J, Minden MD, Pond GR, Schuh AC, Wells RA, Messner H, Chun K, Schimmer AD.

Apoptosis. 2005 Dec;10(6):1285-94.

PMID:
16215669

Supplemental Content

Loading ...
Support Center